Skip to main content

Table 1 hrHPV positivity (any and specific genotypes) for urine, vaginal and cervical samples

From: Urine collection in cervical cancer screening – analytical comparison of two HPV DNA assays

hrHPV result

Assay

(total)

Urine positive

n, % (95%CI)

Vaginal positive

n, % (95%CI)

Cervical positive

n, % (95%CI)

McNemar test

Urine vs. vaginal

McNemar test

Urine vs. cervical

Any hrHPV (14 types)a

Cobas

(n = 150)

27

18.0 (12.2–25.1)

44

29.3 (22.2–37.3)

36

24.0 (17.4–31.6)

0.01

0.05

Clart

(n = 150)

25

16.7 (11.1–23.6)

35

23.3 (16.8–30.9)

31

20.7 (14.5–28.0)

0.04

0.31

HPV16/18b,d

Cobas

(n = 150)

6

4.0 (1.5–8.5)

17

11.3 (6.7–17.5)

15

10.0 (5.7–15.9)

0.01

0.02

Clart

(n = 150)

4

2.7 (0.7–6.7)

9

6.0 (2.8–11.1)

8

5.3 (2.3–10.2)

0.06

0.13

hrHPV other (12 types)c,d

Cobas

(n = 150)

24

16.0 (10.5–22.9)

38

25.3 (18.6–33.1)

29

19.3 (13.3–26.6)

0.01

0.27

Clart

(n = 150)

21

14.0 (8.9–20.6)

31

20.7 (14.5–28.0)

29

19.3 (13.3–26.6)

0.04

0.17

  1. a Any hrHPV: HPV16 and/or HPV18 and/or HPV31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68
  2. b HPV16/18: HPV16 and/or HPV18 including co-infections with hrHPV of other types
  3. c HrHPV other: HPV31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68 including co-infections with HPV16/18
  4. McNemars test comparing the hrHPV positivity proportions between sample types
  5. d Women with co-infections with HPV16/18 and hrHPV of other types appear in both sub-analyses
  6. % Row percentage